BLOOD PRESSURE PROCEDURE
Benefits and risks
The renal denervation blood pressure procedure may help reduce high blood pressure (hypertension),1–3 which is shown to lower your risk of heart attacks, strokes, and other serious health problems.4
Reducing hypertension can lower some of the health risks.
Reducing blood pressure by 10 mmHg can lower risk of:
heart failure4
↓28%
cardiovascular events4
↓20%
stroke4
↓27%
Benefits
Thinking beyond medicaton
While it may not affect how many medications are required, the renal denervation blood pressure procedure may help reduce high blood pressure without the need to add extra medications to a daily regimen5,6
It can help achieve long-term reductions without some of the side effects that may be associated with medications5,6
Who can this procedure help?
The renal denervation blood pressure procedure can help people who are concerned about the health risks of high blood pressure and are interested in all the available treatment options.
- It’s another way to help reduce blood pressure1-3 and reduce serious hypertension-related health risks4
- It may be an option for people with uncontrolled high blood pressure, irrespective of how many medications have been tried or when high blood pressure was first diagnosed1,2
-18.7
mmHg
blood pressure reduction in a three-year study of people who received the renal denervation blood pressure procedure, who were also on medications5
How to learn more
The decision whether or not to have the renal denervation blood pressure procedure is made jointly by the patient and their medical team. The medical team may include a General Practitioner (GP), a specialist doctor such as a cardiologist or renal physician, and the doctor who will perform the procedure (the proceduralist).
- Each patient’s individual medical profile, circumstances and personal preferences should all be taken into account. A series of tests may be required to confirm suitability of the renal denervation blood pressure procedure for each patient.
- Each patient should consult with their doctor to learn more about the renal denervation procedure, and to decide together whether it may be a suitable option to help manage their blood pressure.
Risks
What are the risks of the renal denervation blood pressure procedure?
The renal denervation blood pressure procedure, just like any medical procedure, has risks. Clinical studies show that these risks and side effects are rare5, however, it's important to talk with your doctor about the benefits and risks.
See how it works.
Get more details about the renal denervation blood pressure procedure.
Always follow the instructions specified by your doctor or the nursing staff. Always follow the discharge instructions provided by your physician after your procedure.
References
1
Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomized, sham-controlled trial. The Lancet 2020: Published online March 29, 2020.
2
Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. The Lancet 2018; Jun 9;391(10137): 2346-55.
3
Townsend RR, Mahfoud F, Kandzari DE, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. The Lancet 2017; 390: 2160–70.
4
Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. . The Lancet 2016; 387: 957-67.
5
Mahfoud F, Kandzari DE, Kario K, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. The Lancet 2022; 399(10234): 1401-10.
6
Bhatt DL, Vaduganathan M, Kandzari DE, et al. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial. The Lancet. Published online September 2022:S0140673622017871.